In Wisconsin, U.S. Senate candidates Tommy Thompson, Mark Neumann and Jeff Fitzgerald condemned the president’s actions.
But in the case of Thompson, his criticism comes with a more complicated past when it comes to the issue of contraception.
In his recent financial disclosure statement, filed last month, Thompson disclosed that he was a director of a company called Evofem from July 2005 until he resigned last month. Thompson also disclosed that he had been paid at least $5,000 by Evofem for consulting services.
Evofem, according to its website, is developing technologies in the field of women’s reproductive health. One of its drugs, Amphora, is being evaluated as a microbicide to protect women from pregnancy.
In August 2006, a company called Instead Inc., which eventually became Evofem, put out a news release quoting Thompson about Amphora. Instead Inc., Thompson said, planned to apply for Food and Drug Administration approval of Amphora as a contraceptive.
Thompson’s financial disclosure statement also listed stock holdings in two companies: Teva Pharmaceuticals and Watson Pharmaceuticals. Thompson said he owned at least $15,000 in stock in Teva and at least $1,000 worth of stock in Watson.
Both companies produce and market emergency contraceptive devices.
Published: Feb 20, 2012